Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8229033.
- Also identified by PMC identifier 489823.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The efficacy of intermittent high-dose vitamin C therapy was evaluated in seven patients with HTLV-I-associated myelopathy (HAM). All HAM patients responded well to this therapy without serious side effects. Grade of disability score improved at 9.7 (SD 5.8) months after the therapy from 7.1 (3.3) to 3.6 (2.0) (p < 0.01). Serum immunosuppressive acidic protein was elevated before and decreased after the therapy from 747 (316) to 398 (86) micrograms/ml (p < 0.05), suggesting favourable immunomodulatory action of vitamin C therapy in HAM patients.
Medical subject headings
- Ascorbic Acid
- Paraparesis, Tropical Spastic